$HIMS
Hims & Hers Health, Inc. Stock $hims

$hims Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021010528 Filed on May 17, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$52.31M	$30.06M
YoY Change	74.01%
Cost Of Revenue	$12.07M	$9.444M
YoY Change	27.77%
Gross Profit	$40.25M	$20.62M
YoY Change	95.19%
Gross Profit Margin	76.93%	68.59%
Selling, General & Admin	$61.70M	$14.06M
YoY Change	338.69%
% of Gross Profit	153.3%	68.21%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$394.0K	$180.0K
YoY Change	118.89%
% of Gross Profit	0.98%	0.87%
Operating Expenses	$88.66M	$26.84M
YoY Change	230.35%
Operating Profit	-$48.41M	-$6.218M
YoY Change	678.53%
Interest Expense	$0.00	$10.00K
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$2.905M	$230.0K
YoY Change	-1363.04%
Pretax Income	-$51.31M	-$5.998M
YoY Change	755.52%
Income Tax	$90.00K	$35.00K
% Of Pretax Income
Net Earnings	-$51.40M	-$6.033M
YoY Change	752.05%
Net Earnings / Revenue	-98.26%	-20.07%
Basic Earnings Per Share	-$0.34	-$0.17
Diluted Earnings Per Share	-$0.34	-$0.17
COMMON SHARES
Basic Shares Outstanding	153.1M shares	34.61M shares
Diluted Shares Outstanding	153.1M shares	34.61M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$323.3M	$1.500M
YoY Change	21451.07%
Cash & Equivalents	$88.17M	$1.482M
Short-Term Investments	$235.1M
Other Short-Term Assets	$5.000K	$100.0K
YoY Change	-95.0%
Inventory	$4.523M
Prepaid Expenses	$8.650M	$117.4K
Receivables	$942.0K
Other Receivables	$0.00
Total Short-Term Assets	$340.2M	$1.599M
YoY Change	21174.86%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$204.7M
YoY Change
Other Assets	$4.848M
YoY Change
Total Long-Term Assets	$5.704M	$204.7M
YoY Change	-97.21%
TOTAL ASSETS
Total Short-Term Assets	$340.2M	$1.599M
Total Long-Term Assets	$5.704M	$204.7M
Total Assets	$345.9M	$206.3M
YoY Change	67.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.23M	$74.55K
YoY Change	17649.55%
Accrued Expenses	$5.823M	$558.6K
YoY Change	942.4%
Deferred Revenue	$624.0K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.68M	$1.167M
YoY Change	1585.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$33.75M	$7.200M
YoY Change	368.81%
Total Long-Term Liabilities	$33.75M	$7.200M
YoY Change	368.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.68M	$1.167M
Total Long-Term Liabilities	$33.75M	$7.200M
Total Liabilities	$53.43M	$8.361M
YoY Change	539.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$222.7M	$2.481M
YoY Change	-9075.03%
Common Stock	$515.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$292.5M	-$140.0M
YoY Change
Total Liabilities & Shareholders Equity	$345.9M	$206.3M
YoY Change	67.68%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$51.40M	-$6.033M
YoY Change	752.05%
Depreciation, Depletion And Amortization	$394.0K	$180.0K
YoY Change	118.89%
Cash From Operating Activities	-$15.95M	-$5.191M
YoY Change	207.22%
INVESTING ACTIVITIES
Capital Expenditures	-$803.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$162.5M
YoY Change
Cash From Investing Activities	-$163.3M	$7.233M
YoY Change	-2358.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$22.03M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$239.9M	$30.34M
YoY Change	690.98%
NET CHANGE
Cash From Operating Activities	-$15.95M	-$5.191M
Cash From Investing Activities	-$163.3M	$7.233M
Cash From Financing Activities	$239.9M	$30.34M
Net Change In Cash	$60.68M	$32.37M
YoY Change	87.45%
FREE CASH FLOW
Cash From Operating Activities	-$15.95M	-$5.191M
Capital Expenditures	-$803.0K
Free Cash Flow	-$15.15M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001773751
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	hims	Reverse Capitalization Contingent Consideration Equity Earnout Period ReverseCapitalizationContingentConsiderationEquityEarnoutPeriod	P5Y
CY2020Q1	hims	Lessee Operating Lease Period For Payments Net Of Rent Abatement LesseeOperatingLeasePeriodForPaymentsNetOfRentAbatement	P3M
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	HIMS & HERS HEALTH, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity File Number EntityFileNumber	001-38986
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1482650
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2269 Chestnut Street, #523
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94123
CY2021Q1	dei	City Area Code CityAreaCode	415
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	851-0195
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88169000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27344000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	235097000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	72864000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	4523000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3543000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12407000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5404000	USD
CY2021Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	0	USD
CY2020Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	3929000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	340196000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	113084000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	856000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1006000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4848000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4607000	USD
CY2021Q1	us-gaap	Assets Assets	345900000	USD
CY2020Q4	us-gaap	Assets Assets	118697000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13233000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8066000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5823000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4984000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	624000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1272000	USD
CY2020Q1	hims	Warrants And Rights Outstanding Current WarrantsAndRightsOutstandingCurrent	0	USD
CY2020Q4	hims	Warrants And Rights Outstanding Current WarrantsAndRightsOutstandingCurrent	906000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19680000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15228000	USD
CY2021Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	33370000	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2021Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	384000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	381000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	53434000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	15609000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	275000000	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	93328118	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	249962000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	93328118	shares
CY2021Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	95997674	shares
CY2021Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	268452000	USD
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	249962000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	515216000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	24429000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-72000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-222696000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171292000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	292466000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-146874000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	345900000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118697000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52314000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30063000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	12067000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	9444000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	40247000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	20619000	USD
CY2021Q1	us-gaap	Marketing Expense MarketingExpense	26958000	USD
CY2020Q1	us-gaap	Marketing Expense MarketingExpense	12773000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61698000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14064000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	88656000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	26837000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-48409000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6218000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	10000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2905000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	230000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51314000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5998000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	90000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-51404000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6033000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-61000	USD
CY2021Q1	hims	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	129659000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-51404000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6033000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-42000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51465000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6075000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153080538	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153080538	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34610061	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34610061	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-146874000	USD
CY2021Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	21902000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	249837000	USD
CY2021Q1	hims	Adjustments To Additional Paid In Capital Related Party Receivable Repayment AdjustmentsToAdditionalPaidInCapitalRelatedPartyReceivableRepayment	854000	USD
CY2021Q1	hims	Adjustments To Additional Paid In Capital Warrant Conversion AdjustmentsToAdditionalPaidInCapitalWarrantConversion	1160000	USD
CY2021Q1	hims	Stock Issued During Period Value Contingent Consideration Reverse Recapitalization StockIssuedDuringPeriodValueContingentConsiderationReverseRecapitalization	1000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	80000	USD
CY2021Q1	hims	Adjustments To Additional Paid In Capital Early Exercised Options Vested AdjustmentsToAdditionalPaidInCapitalEarlyExercisedOptionsVested	54000	USD
CY2021Q1	hims	Adjustments To Additional Paid In Capital Recapitalization Warrant Expense AdjustmentsToAdditionalPaidInCapitalRecapitalizationWarrantExpense	-154000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34230000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-61000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-51404000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	292466000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-139793000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2020Q1	hims	Adjustments To Additional Paid In Capital Early Exercised Options Vested AdjustmentsToAdditionalPaidInCapitalEarlyExercisedOptionsVested	11000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1404000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4500000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-42000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6033000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-139953000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	394000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	180000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	34230000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1404000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2681000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-71000	USD
CY2021Q1	hims	Noncash Warrant Expense NoncashWarrantExpense	154000	USD
CY2020Q1	hims	Noncash Warrant Expense NoncashWarrantExpense	0	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	144000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	84000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-452000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	16000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	980000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2000000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7147000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	471000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	58000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-733000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5117000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	674000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1114000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	199000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-648000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	126000	USD
CY2021Q1	hims	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	3000	USD
CY2020Q1	hims	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15948000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5191000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	172021000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	17642000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	9500000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	19200000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	6400000	USD
CY2021Q1	us-gaap	Payments For Software PaymentsForSoftware	740000	USD
CY2020Q1	us-gaap	Payments For Software PaymentsForSoftware	452000	USD
CY2021Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	63000	USD
CY2020Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	273000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-163324000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7233000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	31600000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	89000	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	22027000	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2021Q1	hims	Proceeds From Issuance Of Common Stock Recapitalization ProceedsFromIssuanceOfCommonStockRecapitalization	197686000	USD
CY2020Q1	hims	Proceeds From Issuance Of Common Stock Recapitalization ProceedsFromIssuanceOfCommonStockRecapitalization	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	75000000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	12794000	USD
CY2021Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1193000	USD
CY2020Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	807000	USD
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021Q1	hims	Proceeds From Stock Options Exercised Net Of Repurchases ProceedsFromStockOptionsExercisedNetOfRepurchases	80000	USD
CY2020Q1	hims	Proceeds From Stock Options Exercised Net Of Repurchases ProceedsFromStockOptionsExercisedNetOfRepurchases	-18000	USD
CY2021Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2020Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	1158000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	239945000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30335000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-9000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60675000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32368000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	8000	USD
CY2021Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	125000	USD
CY2020Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28350000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22797000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89025000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55165000	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	59000	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	69000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	249837000	USD
CY2020Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2021Q1	hims	Warrants Assumed WarrantsAssumed	51814000	USD
CY2020Q1	hims	Warrants Assumed WarrantsAssumed	0	USD
CY2021Q1	hims	Warrants Issued WarrantsIssued	20871000	USD
CY2020Q1	hims	Warrants Issued WarrantsIssued	0	USD
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Reclassification Of Deferred Transaction Costs ReclassificationOfDeferredTransactionCosts	3929000	USD
CY2020Q1	hims	Reclassification Of Deferred Transaction Costs ReclassificationOfDeferredTransactionCosts	0	USD
CY2021Q1	hims	Conversion Of Preferred Stock Warrants Amount Converted ConversionOfPreferredStockWarrantsAmountConverted	1160000	USD
CY2020Q1	hims	Conversion Of Preferred Stock Warrants Amount Converted ConversionOfPreferredStockWarrantsAmountConverted	0	USD
CY2021Q1	hims	Transaction Costs Incurred But Not Yet Paid TransactionCostsIncurredButNotYetPaid	511000	USD
CY2020Q1	hims	Transaction Costs Incurred But Not Yet Paid TransactionCostsIncurredButNotYetPaid	0	USD
CY2021Q1	hims	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	54000	USD
CY2020Q1	hims	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	11000	USD
CY2021Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020Q1	us-gaap	Stock Issued1 StockIssued1	4500000	USD
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation and recognition of warrants, and estimates in capitalization of website development and internal-use software costs. Management believes that the estimates and judgments upon which it relies, are reasonable based upon information available to it at the time that these estimates and judgments were made. Actual results experienced by the Company may differ from management's estimates. To the extent that there are material differences between these estimates and actual results, the Company's condensed consolidated financial statements will be affected.
CY2020Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2021Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	100000	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	100000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52314000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30063000	USD
CY2021Q1	hims	Reverse Recapitalization Percentage Of Voting Interests Acquired ReverseRecapitalizationPercentageOfVotingInterestsAcquired	1
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Proceeds From Issuance Of Common Stock Recapitalization ProceedsFromIssuanceOfCommonStockRecapitalization	197700000	USD
CY2021Q1	hims	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	16200000	USD
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Reverse Capitalization Contingent Consideration Equity Shares ReverseCapitalizationContingentConsiderationEquityShares	16000000	shares
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger One ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerOne	15.00
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger Two ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerTwo	17.50
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger Three ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerThree	20.00
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	10	D
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Day Period ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDayPeriod	20	D
CY2021Q1	hims	Reverse Capitalization Contingent Consideration Equity Earnout Period ReverseCapitalizationContingentConsiderationEquityEarnoutPeriod	P5Y
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	235156000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	10	day
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	62000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	235097000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	72859000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	72864000	USD
CY2021Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3546000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2856000	USD
CY2021Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	977000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	687000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	4523000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3543000	USD
CY2021Q1	hims	Trade And Other Receivables Current TradeAndOtherReceivablesCurrent	942000	USD
CY2020Q4	hims	Trade And Other Receivables Current TradeAndOtherReceivablesCurrent	1147000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8650000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2691000	USD
CY2021Q1	hims	Vendor Deposits Current VendorDepositsCurrent	2810000	USD
CY2020Q4	hims	Vendor Deposits Current VendorDepositsCurrent	1395000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	5000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	171000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12407000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5404000	USD
CY2021Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1514000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1122000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1480000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1241000	USD
CY2021Q1	hims	Accrued Payroll Costs Current AccruedPayrollCostsCurrent	1250000	USD
CY2020Q4	hims	Accrued Payroll Costs Current AccruedPayrollCostsCurrent	919000	USD
CY2021Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	729000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	651000	USD
CY2021Q1	us-gaap	Deposit Liability Current DepositLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	664000	USD
CY2021Q1	hims	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Early Exercises Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisesNumberOfShares	301893	shares
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	850000	USD
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger Three ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerThree	20.00
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	387000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5823000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4984000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	300000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	906000	USD
CY2021Q1	hims	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reverse Recapitalization FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReverseRecapitalization	1160000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	51814000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-20871000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2681000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	33370000	USD
CY2021Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
CY2020Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2020Q1	hims	Operating Lease Term Of Contract OperatingLeaseTermOfContract	P63M
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7900000	USD
CY2020Q1	hims	Operating Lease Rent Expense Annual Escalation Percent OperatingLeaseRentExpenseAnnualEscalationPercent	0.025
CY2020Q1	hims	Operating Lease Renewal Term OperatingLeaseRenewalTerm	P5Y
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1146000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1559000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1598000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1638000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1114000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7055000	USD
CY2021Q1	us-gaap	Purchase Obligation PurchaseObligation	1000000.0	USD
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.34
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000.0	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	0	USD
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger Two ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerTwo	17.50
CY2021Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	11968000	shares
CY2021Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	11165000	shares
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger One ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerOne	15.00
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger Two ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerTwo	17.50
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger Three ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerThree	20.00
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	10	day
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	20	day
CY2021Q1	hims	Reverse Capitalization Contingent Consideration Equity Earnout Period ReverseCapitalizationContingentConsiderationEquityEarnoutPeriod	P5Y
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger One ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerOne	15.00
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	20	day
CY2021Q1	hims	Reverse Capitalization Contingent Consideration Equity Earnout Period ReverseCapitalizationContingentConsiderationEquityEarnoutPeriod	P5Y
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34230000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1404000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	95997674	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	95997674	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	93328118	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	93328118	shares
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	268452000	USD
CY2020	hims	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	238641000	USD
CY2021Q1	hims	Recapitalization Exchange Conversion Basis RecapitalizationExchangeConversionBasis	1
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Number Of Classes Of Common Stock NumberOfClassesOfCommonStock	2	common_stock_class
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.4530
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger One ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerOne	15.00
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger Two ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerTwo	17.50
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Stock Price Trigger Three ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTriggerThree	20.00
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	10	day
CY2021Q1	hims	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	20	day
CY2021Q1	hims	Reverse Capitalization Contingent Consideration Equity Earnout Period ReverseCapitalizationContingentConsiderationEquityEarnoutPeriod	P5Y
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.006
CY2021Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2020Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002

Files In Submission

Name	View Source	Status
0001628280-21-010528-index-headers.html	Edgar Link	pending
0001628280-21-010528-index.html	Edgar Link	pending
0001628280-21-010528.txt	Edgar Link	pending
0001628280-21-010528-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hims-20210331.htm	Edgar Link	pending
hims-20210331.xsd	Edgar Link	pending
hims-20210331x10qxex311.htm	Edgar Link	pending
hims-20210331x10qxex312.htm	Edgar Link	pending
hims-20210331x10qxex321.htm	Edgar Link	pending
hims-20210331x10qxex322.htm	Edgar Link	pending
hims-20210331_cal.xml	Edgar Link	unprocessable
hims-20210331_def.xml	Edgar Link	unprocessable
hims-20210331_htm.xml	Edgar Link	completed
hims-20210331_lab.xml	Edgar Link	unprocessable
hims-20210331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HIMS
Hims & Hers Health, Inc. Stock $hims

2021 Q1 Form 10-Q Financial Statement

#000162828021010528 Filed on May 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HIMS Hims & Hers Health, Inc. Stock $hims

2021 Q1 Form 10-Q Financial Statement

#000162828021010528 Filed on May 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HIMS
Hims & Hers Health, Inc. Stock $hims